Atyr Pharma Inc
LIFE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8B
Close$
$3.42
92.1% downside
Current Fair Value
92.1% downsideOvervalued by 92.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.80 Billion |
|---|---|
| Enterprise Value | $2.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.14 |
| Beta | 4.21 |
| Outstanding Shares | 63,480,000 |
Return
| Return on Equity | -124.64% |
|---|---|
| Return on Assets | -87.08% |
| Return on Invested Capital | -109.29% |
Valuation & Multiples
| P/E Ratio | -16.45 |
|---|---|
| PEG | 34.84 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14715.52 |
| Enterprise Value to EBIT | -43.78 |
| Enterprise Value to Net Income | -46 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.37
Average shareholder expectationRevenue Estimate
$117.31 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$169.05 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 33.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 61.42% |
|---|---|
| Total Invested | $15,756▼ 99.93% |
| Investors Holding | 1▼ 98.00% |
ESG Score
No data
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...